Abstract: A syringe assembly (2) comprises a syringe barrel (4) comprising an inner chamber (14) filled or adapted to be filled with medicament, and a channel (18) in fluid communication with the chamber and through which medicament is dispensed. The assembly further comprises an outer sheath (6) configured to be removably attached to the syringe barrel, and comprising a projection (40) which is received by the channel when the outer sheath is attached to the barrel, thereby creating a seal, which prevents medicament from flowing therethrough.

Abstract: This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher, the composition comprises less than about 200 mg/ml cyclodextrin, and at least about 50% of the midazolam is present in solution. Uses of these compositions are also disclosed.

Abstract: A liquid composition for administration to the buccal cavity of a patient comprising less than 10 mg/ml morphine and a pharmaceutically acceptable carrier

Abstract: Unit-dose containers and kits for administering liquid medicament to the buccal cavity of a patient, and related methods of manufacturing such containers, are described. The containers may include a chamber, with a liquid medicament housed therein, and a squeezable region used to deploy the medicament. The container also includes sealing means to prevent premature deployment of the medicament. The container also includes an elongated dispensing tube, approximately 1 to 12 cm in length, in fluid communication with the chamber. The length of the dispensing tube may be sufficient to allow, for example, the distal end of the tube to be located within the buccal cavity of most patients, without the user's hand having to be located between the jaws of the patient.

Abstract: A liquid pharmaceutical composition is described comprising from about 7.5 mg/mL to about 12.5 mg/mL of midazolam in the form of midazolam maleate in solution in an aqueous liquid medium comprising ethanol and a polyhydroxy solvent. This composition can be administered by the buccal route for the treatment of patients suffering epileptic siezures or as an anaesthetic.

Abstract: A pharmaceutical composition is disclosed comprising sodium 4-phenylbutyrate, an effective amount of at least one aromatic flavoring agent, and an effective amount of at least one synthetic sweetening agent. Also disclosed is a method of treatment of a urea cycle deficiency or sickle-cell anaemia.

Abstract: A liquid pharmaceutical composition is described comprising from about 7.5 mg/mL to about 12.5 mg/mL of midazolam in the form of midazolam maleate in solution in an aqueous liquid medium comprising ethanol and a polyhydroxy solvent. This composition can be administered by the buccal route for the treatment of patients suffering epileptic fits or as an anaesthetic.